IRVINE, Calif., March 17, 2006 (PRIMEZONE) -- "One of the most exciting areas of emerging antiretrovirals is the 'entry inhibitors,' a new class of HIV/AIDS therapeutics that are intended to protect healthy cells from viral infection, which are expected to be a life-saving medical breakthrough for HIV drug-resistant patients running out of treatment options," said SmallCap Sentinel analyst D.R. Clark. "With the number of worldwide HIV infections and drug resistance climbing, four drug companies; Pfizer (NYSE:PFE), Schering-Plough (NYSE:SGP), Samaritan Pharmaceuticals, Inc. (AMEX:LIV), and AnorMED (AMEX:AOM), are conducting clinical trials with experimental oral entry inhibitors that block HIV instead of the currently-approved, expensive injections on the market."
"Last week, Samaritan Pharmaceuticals announced it had begun a second Phase II Monotherapy trial of its lead oral entry inhibitor anti-viral agent SP01A, in HIV-infected patients that have shown resistance to other treatments," said Clark. "Also, Schering-Plough provided an update on its Phase II Study of Vicriviroc and stated it will continue in HIV treatment-experienced patients."
The informational report, "The Silver Tsunami: Baby Boomers & Biotech Breakthroughs," addressing the aforementioned companies and others, is available at www.SmallCapSentinel.com.
Samaritan is a drug development company driven to discover, develop and commercialize new, innovative drugs for AIDS, Alzheimer's, Cancer and Heart disease. Samaritan is currently advancing eight promising compounds out of its rich pipeline of 250 possible drug candidates, all of which have the potential to create revenue-generating opportunities.
A free detailed informational report regarding Samaritan is available at the following link: http://stockupticks.com/profiles/3-15-06.html
A Research Report on Samaritan Pharmaceuticals can be downloaded at the company's website: http://www.shareholder.com/samaritan/reports.cfm
Individuals may also register to receive future reports at: http://stockupticks.com/register.html
SmallCap Sentinel and StockUpTicks.com are publications of financial courier Market Pathways, a twenty-two year old full-service financial relations firm offering information on specific public companies to interested investors. To have your company featured in StockUpTicks or SmallCap Sentinel, please use the contact information below.
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that will affect results. SmallCapSentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to accuracy or completeness. This report is neither a solicitation to buy or offer to sell securities but is rather a paid advertisement provided for information purposes only and shouldn't be used as the basis for investment decisions. MP is not an investment advisor and this report is not investment advice. MP was paid $5,000 by Samaritan Pharmaceuticals for preparation of this profile and other advertising services. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.